557 related articles for article (PubMed ID: 23886432)
1. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
2. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
[TBL] [Abstract][Full Text] [Related]
3. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis.
Okamoto Y; Fujieda S; Okano M; Yoshida Y; Kakudo S; Masuyama K
Allergy; 2017 Mar; 72(3):435-443. PubMed ID: 27471838
[TBL] [Abstract][Full Text] [Related]
4. Short-term and long-term efficacy of sublingual immunotherapy in different courses for house dust mite-induced allergic rhinitis.
Yang J; Zheng J; Zhou Y; Qiu Q; Zhan J; Wei X
Am J Otolaryngol; 2024; 45(2):104118. PubMed ID: 38041893
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of 300 IR house dust mite immunotherapy as a function of disease activity: Tertile analysis in clinical trials.
Devillier P; Demoly P; Gentil C; Bergmann KC; Casale TB; Okamoto Y; Pfaar O
Clin Exp Allergy; 2024 May; 54(5):329-338. PubMed ID: 38545699
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis.
Devillier P; Dreyfus JF; Demoly P; Calderón MA
BMC Med; 2014 May; 12():71. PubMed ID: 24885894
[TBL] [Abstract][Full Text] [Related]
7. Quality of life improvement after a three-year course of sublingual immunotherapy in patients with house dust mite and grass pollen induced allergic rhinitis: results from real-life.
Novakova SM; Staevska MT; Novakova PI; Yoncheva MD; Bratoycheva MS; Musurlieva NM; Tzekov VD; Nicolov DG
Health Qual Life Outcomes; 2017 Sep; 15(1):189. PubMed ID: 28962623
[TBL] [Abstract][Full Text] [Related]
8. House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study.
Jutel M; Klimek L; Richter H; Brüggenjürgen B; Vogelberg C
Allergy; 2024 Apr; 79(4):1042-1051. PubMed ID: 38429981
[TBL] [Abstract][Full Text] [Related]
9. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma.
Blumberga G; Groes L; Dahl R
Allergy; 2011 Feb; 66(2):178-85. PubMed ID: 20883456
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous allergen immunotherapy for asthma: A randomized, double-blind, placebo-controlled study with a standardized
Castro-Almarales RL; Ronquillo-Díaz M; Álvarez-Castelló M; Rodríguez-Canosa J; González-León M; Enríquez-Domínguez I; Navarro-Viltre BI; Mateo-Morejón M; Oliva-Díaz Y; Ramírez-González W; Cox L; Labrada-Rosado A
World Allergy Organ J; 2020 Apr; 13(4):100098. PubMed ID: 32308779
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sublingual versus subcutaneous immunotherapy in children with allergic rhinitis: a systematic review and meta-analysis.
Yang J; Lei S
Front Immunol; 2023; 14():1274241. PubMed ID: 38162647
[TBL] [Abstract][Full Text] [Related]
12. Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma.
Hoof I; Bønnelykke K; Stranzl T; Brand S; Li X; Shamji MH; Meyers DA; Bateman ED; Bleecker E; Andersen PS
Thorax; 2024 Mar; 79(4):332-339. PubMed ID: 38160049
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of local allergic rhinitis sensitized to house dust mites in Asia.
Kim SJ; Moon JW; Cho Y; Lee HM
Eur Arch Otorhinolaryngol; 2024 May; 281(5):2413-2420. PubMed ID: 38147114
[TBL] [Abstract][Full Text] [Related]
14. SQ sublingual immunotherapy tablets for children with allergic rhinitis: A review of phase three trials.
Csonka P; Hamelmann E; Turkalj M; Roberts G; Mack DP
Acta Paediatr; 2024 Jun; 113(6):1209-1220. PubMed ID: 38529710
[TBL] [Abstract][Full Text] [Related]
15. How reliable is anamnestic data in predicting the clinical relevance of house dust mite sensitization?
Englhard AS; Holzer M; Eder K; Gellrich D; Gröger M
Eur Arch Otorhinolaryngol; 2022 Feb; 279(2):801-810. PubMed ID: 34019148
[TBL] [Abstract][Full Text] [Related]
16. Circulating T follicular helper 2 cells, T follicular regulatory cells and regulatory B cells are effective biomarkers for predicting the response to house dust mite sublingual immunotherapy in patients with allergic respiratory diseases.
Shigehara K; Kamekura R; Ikegami I; Sakamoto H; Yanagi M; Kamiya S; Kodama K; Asai Y; Miyajima S; Nishikiori H; Uno E; Yamamoto K; Takano K; Chiba H; Ohnishi H; Ichimiya S
Front Immunol; 2023; 14():1284205. PubMed ID: 38111589
[TBL] [Abstract][Full Text] [Related]
17. A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients.
Hüser C; Dieterich P; Singh J; Shah-Hosseini K; Allekotte S; Lehmacher W; Compalati E; Mösges R
Allergy; 2017 Jan; 72(1):77-84. PubMed ID: 27068870
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a murine asthma model.
Hesse L; van Ieperen N; Habraken C; Petersen AH; Korn S; Smilda T; Goedewaagen B; Ruiters MH; van der Graaf AC; Nawijn MC
Allergy; 2018 Apr; 73(4):862-874. PubMed ID: 29318623
[TBL] [Abstract][Full Text] [Related]
19. [An analysis of skin prick test reactivity to dust mite in overweight and normal weight children with allergic asthma before and after specific immunotherapy].
Wang J; Huang Y; Zhang XL; Huang X; Xu XW; Liang FM
Zhongguo Dang Dai Er Ke Za Zhi; 2016 Apr; 18(4):329-34. PubMed ID: 27097578
[TBL] [Abstract][Full Text] [Related]
20. Utility of silver birch and house dust mite extracts derived from licensed sublingual tablets for nasal allergen challenge.
Olivieri B; Gil AJ; Stoenchev K; Durham SR; Scadding G
Clin Transl Allergy; 2024 May; 14(5):e12360. PubMed ID: 38779783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
